Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome

E Niv, A Halak, E Tiommny, H Yanai, H Strul, T Naftali, N Vaisman, E Niv, A Halak, E Tiommny, H Yanai, H Strul, T Naftali, N Vaisman

Abstract

Background: The treatment of Irritable bowel syndrome (IBS) is still challenging. Partially hydrolyzed guar gum (PHGG) is a known prebiotic fiber. To assess the effects of PHGG on clinical symptoms of IBS patients in a prospective randomized double blind placebo-controlled study.

Methods: Suitable IBS patients were recruited into an 18-week-long study (2 weeks of run-in, 12 weeks of treatment and 4 weeks of follow-up). They were blindly randomized to receive 6 gr of PHGG or placebo. Treatment efficacy was evaluated by the Francis Severity IBS score, the IBS quality-of-life scores and scored parameters of weekly journal of symptoms. Deltas of changes between the final and baseline scores were compared between two groups.

Results: Of 121 patients who underwent randomization, 108 patients (49 in the PHGG group and 59 in the placebo group) had all the data needed for intention-to-treat analysis. A 12-week administration of PHGG led to a significant improvement of journal bloating score in the PHGG group versus placebo (-4.1±13.4 versus -1.2±11.9, P=0.03), as well as in bloating+gasses score (-4.3±10.4 versus -1.12±10.5, P = 0.035). The effect lasted for at least 4 weeks after the last PHGG administration. PHGG had no effect on other journal reported IBS symptoms or on Severity and Quality of life scores. There were no significant side effects associated with PHGG ingestion. The rate of dropouts was significantly higher among patients in the placebo group compared with the PHGG group (49.15% versus 22.45%, respectively, P = 0.01).

Conclusions: The results of this study support the administration of 6 g/day PHGG for IBS patients with bloating.

Trial registration: NCT01779765.

Keywords: Fibers; Irritable bowel syndrome (IBS); Partially hydrolyzed guar gum (PHGG); Prebiotics.

Figures

Fig. 1
Fig. 1
Dynamic changes in IBS parameters over 3 months of treatment expressed as delta from the baseline values

References

    1. Olden K. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002;122:1701–14. doi: 10.1053/gast.2002.33741.
    1. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol. 2003;98:600–7. doi: 10.1111/j.1572-0241.2003.07296.x.
    1. Akehurst R, Kaltenhaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut. 2001;48:272–82. doi: 10.1136/gut.48.2.272.
    1. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20(Suppl 2):1–9. doi: 10.1111/j.1365-2036.2004.02036.x.
    1. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38(Suppl 6):S104–6. doi: 10.1097/01.mcg.0000129271.98814.e2.
    1. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study. Clin Nutr. 2005;24:925–31. doi: 10.1016/j.clnu.2005.06.001.
    1. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microflora—introducing the concept of prebiotics. J Nutr. 1995;125:1401–12.
    1. Tuohy KM, Kolida S, Lustenberger AM, Gibson GR. The prebiotic effects of biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides—a human volunteer study. Br J Nutr. 2001;86:341–8. doi: 10.1079/BJN2001394.
    1. Okubo T, Ishihara N, Takahashi H, Ishihara N, Yamanaka J, Yamamoto T, et al. Effects of partially hydrolyzed guar gum intake on human intestinal microflora and its metabolism. Biosci Biotechnol Biochem. 1994;58:1364–9. doi: 10.1271/bbb.58.1364.
    1. Takahashi H, Yang SI, Hayashi CH, Kim M, Yamanaka J, Yamamoto T. Effect of partially hydrolysed guar gum on fecal output in human volunteers. Nutr Res. 1993;13:649–57. doi: 10.1016/S0271-5317(05)80557-3.
    1. Takahashi H, Wako N, Okubo T, Ishihara N, Yamanaka J, Yamamoto T. Influence of partially hydrolysed guar gum on constipation in women. J Nutr Sci Vitaminol. 1994;40:251–9. doi: 10.3177/jnsv.40.251.
    1. Weaver GA, Tangel C, Krause JA, Alpern HD, Jenkins PL, Parfitt MM, et al. Dietary guar gum alters colonic microbial fermentation in azoxymethane-treated rats. J Nutr. 1996;126:1979–81.
    1. Phillips SF. Physiology and pathophysiology of the colon: relationship to constipation. In: Barbara L, Corinaldesi R, Gizzi G, Stanghellini V, editors. Chronic constipation. London: WB Saunders; 1996. pp. 19–37.
    1. Jenkins DJ, Leeds AR, Slavin B, Mann J, Jepson EM. Dietary fiber and blood lipids: reduction of serum cholesterol in type 2 hyperlipidemia by guar gum. Am J Clin Nutr. 1979;32:16–18.
    1. Jenkins DJ, Goff DV, Leeds AR, Alberti KG, Wolever TM, Gassull MA, et al. Unabsorable carbohydrates and diabetes: decreased post–prandial hyperglycemia. Lancet. 1976;2:172–4. doi: 10.1016/S0140-6736(76)92346-1.
    1. Yamatoya K, Sekiya K, Yamada H. Effects of partially hydrolyzed guar gum on postprandial plasma glucose and lipids levels in humans. J Jpn Soc Nutr Food Sci. 1993;46:199–203. doi: 10.4327/jsnfs.46.199.
    1. Alam NH, Meier R, Schneides H, Sarker SA, Bardhan PK, Mahalanabis D, et al. Partially hydrolysed guar gum-supplemented oral rehydration solution in the treatment of acute diarrhoea in children. J Pediatr Gastroenterol Nutr. 2000;31:503–7. doi: 10.1097/00005176-200011000-00010.
    1. Homman HH, Kemen M, Fuessenich C, Senkal M, Zumtobel V. Reduction in diarrhea incidence by soluble fiber in patients receiving total or supplemental enteral nutrition. J Parenter Enteral Nutr. 1994;18:486–90. doi: 10.1177/0148607194018006486.
    1. Rushdi TA, Pichard C, Khater YH. Control of diarrhea by fiber-enriched diet in ICU patients on enteral nutrition: a prospective randomized controlled trial. Clin Nutr. 2004;23:1344–52. doi: 10.1016/j.clnu.2004.04.008.
    1. Yamatoya K, Kuwano K, Suzuki J, Mitamura T, Sekeiya K. Effect of hydrolyzed guar gum on frequency and feeling of defecation in humans. J Appl Glycosci. 1995;42:251–7.
    1. Patrick PG, Gohman SM, Marx SC, DeLegge MH, Greenberg NA. Effect of supplements of partially hydrolyzed guar gum on the occurrence of constipation and use of laxative agents. J Am Diet Assoc. 1998;98:912–4. doi: 10.1016/S0002-8223(98)00210-7.
    1. Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, et al. High-fiber diet supplementation in patients with irritable bowelsyndrome (IBS). Comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG) Dig Dis Sci. 2002;47:1697–704. doi: 10.1023/A:1016419906546.
    1. Parisi G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, et al. Treatment effects of partially hydrolyzed guar gum (PHGG) on symptoms and quality of life of patients with irritable bowel syndrome (IBS). A multicenter, randomized open trial. Dig Dis Sci. 2005;50:1107–12. doi: 10.1007/s10620-005-2713-7.
    1. Giaccari S, Grasso G, Tronci S, Allegretta L, Sponziello G, Montefusco A, et al. Gomma guar parzialmente idrolizzata: una fibra come coadiuvante nella sindrome del colon irritabile. Clin Ter. 2001;152:21–5.
    1. Giannini EG, Mansi C, Dulbecco P, Savarino V. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. Nutrition. 2006;22:334–42. doi: 10.1016/j.nut.2005.10.003.
    1. Russo L, Andreozzi P, Zito FP, Vozzella L, Savino IG, Sarnelli G, et al. Partially hydrolyzed guar gum in the treatment of irritable bowel syndrome with constipation: effects of gender, age, and body mass index. Saudi J Gastroenterol. 2015;21(2):104–10. doi: 10.4103/1319-3767.153835.
    1. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395–402. doi: 10.1046/j.1365-2036.1997.142318000.x.
    1. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QQL: a disease–specific quality–of-life questionnaire. Am J Gastroenterol. 2000;95:999–1007. doi: 10.1111/j.1572-0241.2000.01941.x.
    1. Sperber AD, DeVellis RF, Boehlecke B. Cross-cultural translation: methodology and validation. J Cross-Cult Psychol. 1994;25:501–24. doi: 10.1177/0022022194254006.
    1. Sperber AD. Translation and validation of study instruments for cross-cultural research. Gastroenterology. 2004;126:S124–8. doi: 10.1053/j.gastro.2003.10.016.
    1. Pylkas AM, Juneja LR, Slavin JL. Comparison of different fibers for in vitro production of short-chain fatty acids by intestinal microflora. J Med Foods. 2005;8:113–6. doi: 10.1089/jmf.2005.8.113.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner